TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|January 1, 1999
Supplements and Featured Publications
- Clinical and Therapeutic Advances in the Treatment of Sexual Dysfunction: A Paradigm for Managed Ca
- Volume 5
- Issue 1 Suppl
Introduction
Advertisement
Articles in this issue
almost 28 years ago
Selected Abstractsalmost 28 years ago
CME Quizalmost 28 years ago
Bibliographyalmost 28 years ago
Participating Facultyalmost 28 years ago
An Overview of Erectile Dysfunctionalmost 28 years ago
Health Economics and Sexual Dysfunctionalmost 28 years ago
Managed Care and Sexual Dysfunctionalmost 28 years ago
Cardiovascular Risk Factors and Erectile Dysfunctionalmost 28 years ago
The Psychosocial Context of Sexual DysfunctionAdvertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5